Teva Goes to Trial Over Hepatitis Cases Linked to Tainted Propofol Vials

Rachel Fields - Print  |

Teva Pharmaceutical Industries, the world's largest generic drug manufacturer, is facing a second trial over hepatitis cases linked to propofol, according to a Bloomberg Businessweek report.

According to the report, three Las Vegas residents alleged they were diagnosed with hepatitis after receiving propofol from tainted vials during colonoscopies. The patients' lawyer told jurors yesterday that Teva officials, along with drug distributors Baxter International and McKesson, knew sales of large vials of the drug could spread blood borne diseases.

Teva faces nearly 300 lawsuits surrounding a hepatitis C outbreak three years ago in southern Nevada. Nevada health officials say patients were infected with incurable liver disease through the reuse of propofol vials.

Teva manufactures propofol, and the drug is distributed in the U.S. by McKesson.

Related Articles on Anesthesia:
Awareness Under Anesthesia More Likely With Bispectral Index Protocol
American Society of Anesthesiologists Adds Patient Education Video on Pain Medication
Patients Under General Anesthesia Perceive, Remember Surgery

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.